The global depression treatment Market is anticipated to grow at a CAGR of 4.1% during the forecast period (2021-2027). The increasing number of FDA approvals for antidepressants along with the expansion in pipeline products by key market players is certain factors driving the growth of the depression treatment industry.
In February 2021, Zydus Cadila has received US FDA approval for Nortriptyline Hydrochloride Capsules USP. The capsules come up in the strength of 10 mg, 25 mg, 50 mg, and 75 mg. Nortriptyline Hydrochloride Capsules USP is majorly used for the treatment of depression.
A full report of Depression Treatment Market is available at: https://www.omrglobal.com/industry-reports/depression-treatment-market
Moreover, in July 2020, VistaGen Therapeutics, a US-based biopharmaceutical company had received US FDA approval for PH94B under Phase 3 development to treat acute anxiety and mental illness in adult patients with a social anxiety disorder (SAD). PH94B is an investigational rapid-onset neurosteroid nasal spray majorly used for the treatment of social anxiety disorder.
Furthermore, in March 2019, Johnson & Johnson’s ketamine-derived nasal spray Spravato for treatment-resistant depression has been approved by the FDA. The Spravato CIII Nasal Spray is used for the treatment of depressive disorder in adults with a high risk of major depressive disorder (MDD). Thus, these approvals by the FDA for antidepressant drugs produced by major key players, the depression treatment market is expected to witness significant growth during the forecast period.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/depression-treatment-market
Market Coverage
- The market number available for – 2021-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Drug Type
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- Eli Lilly and Company, Pfizer, Inc., Johnson & Johnson, Merck & Co., Inc., H. Lundbeck A/S, F. Hoffmann-La Roche Ltd, and Others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Depression Treatment Market Report Segment
By Drug Type
- Selective Serotonin Reuptake Inhibitors
- Tricyclic Antidepressants
- Serotonin-Norepinephrine Reuptake Inhibitors
- Monoamine Oxidase Inhibitors
- Others
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
